Leerink Partners Sticks to Their Buy Rating for 2seventy Bio (TSVT)
TipRanksApr 30 02:06 ET
2seventy Bio Analyst Ratings
BenzingaApr 8 18:11 ET
Positive Outlook for 2seventy Bio's ABECMA: Buy Rating Affirmed Amidst Expansion and Competitive Dynamics
TipRanksApr 8 07:25 ET
Buy Rating and High Risk for 2seventy Bio: FDA Approval and Market Expansion Fuel Optimistic Outlook
TipRanksApr 7 15:05 ET
2seventy Bio Analyst Ratings
BenzingaMar 18 08:37 ET
TD Cowen Sticks to Its Hold Rating for 2seventy Bio (TSVT)
TipRanksMar 18 07:15 ET
Analysts Are Bullish on These Healthcare Stocks: 2seventy Bio (TSVT), Immuneering (IMRX)
TipRanksMar 15 07:00 ET
TD Cowen Sticks to Their Hold Rating for 2seventy Bio (TSVT)
TipRanksMar 14 07:36 ET
Optimistic Outlook for 2seventy Bio's ABECMA Ahead of FDA Panel Review: A Buy Rating Justified
TipRanksMar 14 07:17 ET
Buy Rating Affirmed for 2seventy Bio on FDA Meeting and Strong Financial Outlook
TipRanksMar 6 23:20 ET
Analysts Are Bullish on These Healthcare Stocks: Sarepta Therapeutics (SRPT), 2seventy Bio (TSVT)
TipRanksMar 6 06:31 ET
Buy Rating Affirmed for 2seventy Bio Amidst Revenue Stabilization and Strategic Growth Initiatives
TipRanksFeb 3 12:47 ET
2seventy Bio Analyst Ratings
BenzingaJan 31 05:26 ET
Hold Rating for 2seventy Bio Amid Regulatory Risks and Potential Upsides: An Analysis on KarMMa-3 Study Outcomes and Stock Performance
TipRanksNov 22, 2023 06:38 ET
2seventy Bio Analyst Ratings
BenzingaNov 20, 2023 09:56 ET
Samantha Semenkow Maintains Buy Rating for 2seventy Bio Amidst Abecma Revenue Growth Projections and Adjustment in 3L+ MM Forecasts
TipRanksNov 17, 2023 06:24 ET
Daina Graybosch Maintains 'Hold' Rating for 2seventy Bio Amid Revenue Decline and Market Challenges
TipRanksNov 16, 2023 07:26 ET
2seventy Bio's Stock – Potential for Growth Despite Challenges: An Analysis of Yaron Werber's Buy Rating
TipRanksNov 14, 2023 12:55 ET
Wedbush Adjusts 2seventy Bio Price Target to $4 From $7, Maintains Outperform Rating
MT NewswiresNov 14, 2023 12:51 ET
2seventy Bio Analyst Ratings
BenzingaOct 30, 2023 09:30 ET
No Data
No Data